Summary Series

 

March 16, 2021

Discrepancy analysis comparing molecular and histology diagnoses in kidney transplant biopsies

By: Christopher Lawrence

 

 

Key Takeaways

  • MMDx® is an accurate and reproducible measurement of the kidney biopsy.
  • There is minimal inter-observer disagreement in MMDx reporting, in contrast to histopathology.
  • There is significant disagreement between MMDx and histopathology, particularly in boundary states such as “borderline” for TCMR.
  • MMDx can either be sent at the time of biopsy or preserved (frozen in RNAlater) for later reference.

 

Summary Statement

This study demonstrates the reproducibility of MMDx and the lack of significant disagreement between MMDx sign outs.

The study describes in detail where MMDx and histopathology disagree. There is relatively good agreement between histological ABMR and MMDx, but MMDx diagnoses more ABMR than histology. Additionally, there is reasonable agreement in “no rejection” but there is very significant disagreement in TCMR and “borderline for TCMR.”

 

Summary

Diagnostic platforms require precision (reproducibility), accuracy (represent the true disease state), and standardization. Histology has well-described limitations.

The Molecular Microscope Diagnostic System (MMDx) consists of an automated report combining rejection and injury-related scores with a graphic representation of the molecular position of the current biopsy, which is compared to a reference set, and a categorical sign-out by an expert or an algorithm (AutoMMDx).

This study compared the results of 1679 indication biopsies from the 1120 INTERCOMEX trial subjects and compared various discrepancies: within MMDx; between MMDx sign-outs; and between MMD and histology.

The results showed that MMDx outputs (rejection classifiers, etc.) are nearly identical between technical replicates, i.e., a biopsy core divided in two and processed separately gives a 99% correlation. Similarly, MMDx sign-outs between two experts and the automated algorithm were highly correlated. One comparison revealed 6% discrepancies, of which only 1.4% occurred in clear categories. Conversely, MMDx and histology sign-outs disagreed 37% of the time, broken down into 22% in ABMR, 61% in TCMR, and 24% in no rejection.

The histology diagnosis of “borderline for TCMR” was rarely TCMR by MMDx (ABMR 24/128, no rejection 83/128, TCMR 9/128). 49% of MMDx diagnosed ABMR was not ABMR by histology, and although MMDx diagnosed similar numbers of TCMR as by histology, there was extensive disagreement. 68/123 MMDx diagnoses of TCMR were not reported as TCMR by histology. MMDx may offer particular value where pathology is ambiguous, i.e. borderline or suspicious.

If not sending MMDx on all biopsies already, the authors recommend storing a 3mm section of biopsy core in RNA later for use in certain circumstances, such as where MMDx may add clarification:

  1. Where DSA are negative or unclear, and there is a suspicion of ABMR
  2. Where there is “Mixed” rejection
  3. In TCMR, Borderline TCMR and to rule out TCMR co-existing with BK

It would also be sensible to utilize MMDx where patients are re-biopsied because the original biopsy was ambiguous or where the clinical course has not unfolded as expected.

Reference:

Madill-Thomsen K, Perkowska-Ptasińska A, Böhmig GA, Eskandary F, Einecke G, Gupta G, Halloran PF; MMDx-Kidney Study Group. Discrepancy analysis comparing molecular and histology diagnoses in kidney transplant biopsies. Am J Transplant. 2020 May;20(5):1341-1350. doi: 10.1111/ajt.15752. Epub 2020 Jan 23. PMID: 31846554.